LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

Actinium Pharmaceuticals Inc

Aperta

1.45 2.11

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.42

Massimo

1.46

Metriche Chiave

By Trading Economics

Entrata

-9.3M

-16M

EPS

-0.51

Dipendenti

31

EBITDA

-9.3M

-17M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+319.58% upside

Dividendi

By Dow Jones

Utili prossimi

1 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-624K

48M

Apertura precedente

-0.66

Chiusura precedente

1.45

Actinium Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 giu 2025, 17:32 UTC

I principali Market Mover

Lion Group Shares Climb on $600 Million Loan for Crypto Treasury

18 giu 2025, 23:55 UTC

Acquisizioni, Fusioni, Takeovers

Nippon Steel: To Book Restructuring Loss Related to This Sale in 1Q

18 giu 2025, 23:53 UTC

Acquisizioni, Fusioni, Takeovers

Nippon Steel: NS Kote Is an Entity That Owns All of Company's Equity Stake in AM/NS Calvert

18 giu 2025, 23:50 UTC

Acquisizioni, Fusioni, Takeovers

Nippon Steel: To Book About Y230B Loss Related to Sale of NS Kote to ArcelorMittal

18 giu 2025, 23:50 UTC

Discorsi di Mercato

Australian Uranium Stocks Tipped to Go Higher -- Market Talk

18 giu 2025, 23:43 UTC

Discorsi di Mercato

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

18 giu 2025, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

18 giu 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

18 giu 2025, 23:07 UTC

Discorsi di Mercato

Fletcher Building Recovery May Be More Muted Than Thought -- Market Talk

18 giu 2025, 23:00 UTC

Discorsi di Mercato

Smart Glasses Seen as Possible Future Agentic AI Platform -- Market Talk

18 giu 2025, 21:50 UTC

Discorsi di Mercato

Argentina Poised To Become Significant LNG Exporter, Rystad Says -- Market Talk

18 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

18 giu 2025, 20:38 UTC

Acquisizioni, Fusioni, Takeovers

U.S. Steel and Nippon Finalize Their 'Partnership.' What Comes After the Merger. -- Barrons.com

18 giu 2025, 20:32 UTC

Utili

These Stocks Moved the Most Today: Tesla, Marvell, Sunrun, Nucor, Circle Internet, Korn Ferry, GMS, and More -- Barrons.com

18 giu 2025, 19:59 UTC

Discorsi di Mercato

Oil Edges Up as Next Steps in Iran Conflict Eyed -- Market Talk

18 giu 2025, 19:42 UTC

Discorsi di Mercato

Natural Gas Extends Gains for Fourth Session -- Market Talk

18 giu 2025, 19:40 UTC

Utili

Fed Holds Rates Steady and Keeps Door Open to Cuts -- 3rd Update

18 giu 2025, 18:47 UTC

Acquisizioni, Fusioni, Takeovers

Railroads Have Slashed Costs and Raised Prices. Why One CEO Now Favors a Merger. -- Barrons.com

18 giu 2025, 18:33 UTC

Discorsi di Mercato

Fitch Says U.S. Fiscal Outlook Remains Challenging -- Market Talk

18 giu 2025, 18:26 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

18 giu 2025, 18:26 UTC

Discorsi di Mercato

Nucor, Steel Dynamics Seen Diverging In Approach To Current Business Climate -- Market Talk

18 giu 2025, 18:15 UTC

Discorsi di Mercato

Gold Stays Flat After Fed Decision -- Market Talk

18 giu 2025, 17:42 UTC

Acquisizioni, Fusioni, Takeovers

ArcelorMittal Expects Related 2Q Gain of About $1.5B

18 giu 2025, 17:40 UTC

Acquisizioni, Fusioni, Takeovers

ArcelorMittal Completes Acquisition of Nippon Steel's 50% Interest in AM/NS Calvert

18 giu 2025, 17:20 UTC

Utili

Credit Card Annual Fees Are Going Up. What It Means for the Stocks. -- Barrons.com

18 giu 2025, 16:52 UTC

Discorsi di Mercato

Trump Awakens Canada On Need For Fewer Trade Barriers, Macklem Says -- Market Talk

18 giu 2025, 16:31 UTC

Acquisizioni, Fusioni, Takeovers

Nippon Steel Completes Purchase of U.S. Steel After Reaching Security Deal With Trump Administration -- Update

18 giu 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

18 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

18 giu 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Actinium Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

319.58% in crescita

Previsioni per 12 mesi

Media 6 USD  319.58%

Alto 9 USD

Basso 4 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Actinium Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.